ArticleJournal of translational autoimmunity2026
Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation.
Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is an autoimmune hair loss disorder driven by the IFN-γ-JAK-STAT signaling and cytotoxic T-cell attack. Although JAK inhibitors like ruxolitinib show clinical efficacy, their integrated mechanism remains unclear. This study elucidated ruxolitinib's therapeutic actions in a C3H/HeJ mouse model of AA induced by adoptive transfer of activated lymph node cells. Mice were treated daily with ruxolitinib or vehicle for 98 days, with weekly clinical scoring of hair loss. Comprehensive analyses quantified systemic and skin cytokines (IFN-γ, TNF-α, IL-5, IL-6, IL-10, and CXCL1/KC), oxidative stress markers (malondialdehyde [MDA] and superoxide dismutase), apoptosis (cleaved caspase-3), autophagy (LC3-II), immune infiltration (CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.